Because both osimertinib and bevacizumab can penetrate the blood‒brain barrier and have good efficacy in the central nervous system, the combination of bevacizumab with IC for the treatment of EGFR-mutated NSCLC LM warrants further in-depth study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.